Clinical trialsOfficial

FDA closes Expedited IND pilot applications after more than 100 submissions; selections due by 18 December

🇺🇸 FDA CBER · Wed 04 Nov 2026

CBER's pilot under HHS Operation TrialBlazer will test whether outside expert institutions and rolling review can speed first-in-human trials without lowering safety or oversight standards.

The US Food and Drug Administration has closed the application window for its Expedited Investigational New Drug (IND) Pilot Program, saying it received more than 100 applications from sponsors and prospective Qualified Research Institutions (QRIs). The submissions span a range of therapeutic areas, modalities and institution types, all aimed at starting first-in-human trials in the United States. FDA expects to notify selected participants by 18 December.

The pilot, part of HHS Operation TrialBlazer, is designed to shorten the time between the start of IND-enabling work and the first dosing of humans. Under the model, third parties such as academic medical centres, health networks, contract research organisations or regulatory advisers act as QRIs. They would give sponsors expert recommendations on the pharmacology and toxicology, clinical, and chemistry, manufacturing and controls (CMC) parts of a first-in-human IND.

A central feature is rolling review: FDA will accept and review individual IND components as they are finished, rather than waiting for a complete package. The agency says this could let problems be found and fixed earlier, reduce the risk of a clinical hold at the end of the process and make the path to first-in-human studies faster and more predictable. Sponsors remain responsible for their own component submissions. The pilot also encourages coordination of activities such as IRB review and site activation where appropriate.

Participation is voluntary, and FDA stresses that it keeps full regulatory authority, including decisions on whether a study may proceed or be placed on hold. The pilot does not change statutory or regulatory standards for IND review, safe-to-proceed determinations or trial conduct. FDA says it will use the pilot to assess outcomes such as better phase-appropriate data, fewer Phase 1 holds and information requests, and better trial start-up coordination. It adds that the findings could inform future policies, including possible certification or accreditation of QRIs.

The agency also cites a shift of early-stage clinical research overseas as a reason for the initiative. The available text does not set out selection criteria or operational procedures in detail.

What it means for your team

  • Sponsors not selected this round should watch for any follow-on policy, as FDA says the pilot may inform future approaches such as QRI certification or accreditation.
  • Regulatory teams in the pilot would need to plan for component-by-component IND submissions rather than a single complete package, while sponsors remain responsible for their own submissions.
  • QA and CMC teams should note that CMC, nonclinical and clinical input from QRIs is central to the model, but FDA's IND standards and hold authority are unchanged.
  • Early-phase planners may want to align IRB review and site activation with IND preparation, which the pilot explicitly encourages where appropriate.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.

More Clinical trials All →